Company profile
Solianis Holding AG is a medical devices company developing a non-invasive Continuous Glucose Monitor (CGM) for self-monitoring patients with diabetes, within the broader range of physiological monitoring.
In a clinical-experimental trial, conducted in cooperation with the University Hospital Zurich, Solianis has shown that its multi-sensor technology tracks glucose changes in patients with diabetes as well as healthy subjects. In these trials, the subjects have gone through glucose challenges under various conditions designed to test the impact of the additional effects, thus simulating real life conditions.
The results of these trials with healthy subjects as well as patients with diabetes look exciting – proof of concept is reached. In the next clinical trial (“Outpatient study”), started in November 2007, the applicability of the platform will be further demonstrated in an outpatient setting.
|
